ACUR (Acura Pharmaceuticals) Marketable Securities: $0.00 Mil (As of Dec. 2021)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ACUR Acura Pharmaceuticals Inc ACUR
16 GF Score
Price $0.00
View Full Analysis

What is Acura Pharmaceuticals Marketable Securities?

Acura Pharmaceuticals ACUR 16 Marketable Securities is $0.00 Mil as of Dec. 2021. GuruFocus rates ACUR with a GF Score™ of 16/100.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Acura Pharmaceuticals's Marketable Securities for the quarter that ended in Dec. 2021 was $0.00 Mil.

Acura Pharmaceuticals  (OTCPK:ACUR) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Acura Pharmaceuticals Marketable Securities Related Terms

Acura Pharmaceuticals Marketable Securities Historical Data

* Premium members only.

The historical data trend for Acura Pharmaceuticals's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Acura Pharmaceuticals Marketable Securities Chart

Acura Pharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Acura Pharmaceuticals Quarterly Data
Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ACUR
16GF Score
Acura Pharmaceuticals Inc ACUR
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Acura Pharmaceuticals Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $0.00 Mil mean?
Acura Pharmaceuticals (ACUR) has a Marketable Securities of $0.00 Mil as of Dec. 2021. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Acura Pharmaceuticals and its competitors.
Is Acura Pharmaceuticals' Marketable Securities too high?
Acura Pharmaceuticals' current Marketable Securities is $0.00 Mil. Overall, Acura Pharmaceuticals has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Acura Pharmaceuticals' Marketable Securities compare to VFRM and THCT?
Acura Pharmaceuticals' Marketable Securities of $0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Drug Manufacturers company?
A good Marketable Securities depends on the Drug Manufacturers industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Acura Pharmaceuticals and its competitors. Acura Pharmaceuticals's current Marketable Securities is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acura Pharmaceuticals stock overvalued right now?
Acura Pharmaceuticals (ACUR) has a current Marketable Securities of $0.00 Mil. The current Marketable Securities is $0.00 Mil. Acura Pharmaceuticals' overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Acura Pharmaceuticals (ACUR), the current Marketable Securities is $0.00 Mil as of Dec. 2021. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Acura Pharmaceuticals Business Description

Address 616 N. North Court, Suite 120, Palatine, IL, USA, 60067
Acura Pharmaceuticals Inc is a drug delivery company engaged in the research, development and commercialization of technologies and products intended to address safe use of medications. It has discovered and developed three proprietary platform technologies which can be used to develop multiple products. Its Limitx Technology is being developed to minimize the risk of overdose, its Aversion Technology is intended to address methods of abuse associated with opioid analgesics while its Impede Technology is directed at minimizing the extraction and conversion of pseudoephedrine, or PSE, into methamphetamine. It operates in single segment being the research, development and commercialization of technologies and products intended to address safe use of medications.
16GF Score

Get the complete analysis for ACUR

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price